Skip to main content
Northwestern University Feinberg School of Medicine
Schnitzer Lab

Publications

Learn more about the work that we do in the Schnitzer laboratory through our recent publications.

  1. DiMartino SJ, Mei J, Schnitzer TJ, Gao H, Eng S, Winslow C, Ho T, Turner KC, Hassan HE, Patel Y  et al.  A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip.  Osteoarthr Cartil Open  2024 Dec;6(4):100533. pii:100533
  2. Langford DJ, Mark RP, France FO, Nishtar M, Park M, Sharma S, Shklyar IC, Schnitzer TJ, Conaghan PG, Amtmann D  et al.  Use of patient-reported global assessment measures in clinical trials of chronic pain treatments: ACTTION systematic review and considerations.  Pain  2024 Nov 01;165(11):2445-2454. doi:10.1097/j.pain.0000000000003270
  3. Crack LE, Simonian N, Schnitzer TJ, Edwards WB  Monthly treatment with romosozumab for 1 year increases bone mineral at the hip, but not the knee, in women with chronic spinal cord injury.  JBMR Plus  2024 Jul;8(7):ziae077. pii:ziae077
  4. Schnitzer TJ, Conaghan PG, Berenbaum F, Abraham L, Cappelleri JC, Bushmakin AG, Viktrup L, Yang R, Brown MT  Effect size varies based on calculation method and may affect interpretation of treatment effect: an illustration using randomised clinical trials in osteoarthritis.  Adv Rheumatol  2024 Apr 22;64(1):31. doi:10.1186/s42358-024-00358-y
  5. Espinosa-Salas S, Bagherzadeh L, Wafford QE, Witte G, Schnitzer TJ  Does sex affect the efficacy of systemic pharmacological treatments of pain in knee osteoarthritis? A systematic review.  Osteoarthr Cartil Open  2024 Mar;6(1):100438. pii:100438
  6. Baliki MN, Vigotsky AD, Rached G, Jabakhanji R, Huang L, Branco P, Cong O, Griffith J, Wasan AD, Schnitzer TJ  et al.  Neuropsychology of chronic back pain managed with long-term opioid use.  medRxiv  2024 Feb 08;. pii:2024.02.07.24302408
  7. Carrino JA, McAlindon TE, Schnitzer TJ, Guermazi A, Hochberg MC, Conaghan PG, Brown MT, Burr A, Fountaine RJ, Pixton GC  et al.  Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab.  Osteoarthritis Cartilage  2023 Dec;31(12):1612-1626. doi:10.1016/j.joca.2023.08.010
  8. Barroso J, Branco P, Pinto-Ramos J, Vigotsky AD, Reis AM, Schnitzer TJ, Galhardo V, Apkarian AV  Subcortical brain anatomy as a potential biomarker of persistent pain after total knee replacement in osteoarthritis.  Pain  2023 Oct 01;164(10):2306-2315. doi:10.1097/j.pain.0000000000002932
  9. Crack LE, Haider IT, Simonian N, Barroso J, Gabel L, Schnitzer TJ, Edwards WB  Zoledronic acid after spinal cord injury mitigates losses in proximal femoral strength independent of ambulation ability.  Osteoporos Int  2023 Sep;34(9):1637-1645. doi:10.1007/s00198-023-06811-w
  10. Mazur CM, Edwards WB, Haider IT, Fang Y, Morse LR, Schnitzer TJ, Simonian N, Troy KL  Bone Mineral Loss at the Distal Femur and Proximal Tibia Following Spinal Cord Injury in Men and Women.  J Clin Densitom  2023;26(3):101380. doi:10.1016/j.jocd.2023.101380
  11. Schnitzer TJ, Robinson RL, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, Berry M, Walker C, Jackson J  Opioids for Osteoarthritis: Cross-Sectional Survey of Patient Perspectives and Satisfaction.  J Clin Med  2023 Apr 06;12(7). pii:2733
  12. Schnitzer TJ, Robinson RL, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, Berry M, Walker C, Jackson J  Opioid Prescribing for Osteoarthritis: Cross-Sectional Survey among Primary Care Physicians, Rheumatologists, and Orthopaedic Surgeons.  J Clin Med  2023 Jan 11;12(2). pii:589
  13. Atkinson J, Edwards RA, Bonfanti G, Barroso J, Schnitzer TJ  A Two-Step, Trajectory-Focused, Analytics Approach to Attempt Prediction of Analgesic Response in Patients with Moderate-to-Severe Osteoarthritis.  Adv Ther  2023 Jan;40(1):252-264. doi:10.1007/s12325-022-02336-6
  14. Markman JD, Schnitzer TJ, Perrot S, Beydoun SR, Ohtori S, Viktrup L, Yang R, Bramson C, West CR, Verburg KM  Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial.  Pain Ther  2022 Dec;11(4):1267-1285. doi:10.1007/s40122-022-00424-7
  15. Schnitzer TJ, Bonfanti G, Atkinson J, Donevan S, Viktrup L, Barroso J, Whalen E, Edwards RA  Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis.  Adv Ther  2022 Oct;39(10):4742-4756. doi:10.1007/s12325-022-02290-3
  16. Hunter DJ, Schnitzer TJ, Hall J, Semel D, Davignon I, Cappelleri JC, Bushmakin AG, Abraham L  Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab.  Osteoarthr Cartil Open  2022 Sep;4(3):100294. pii:100294
  17. Conaghan PG, Dworkin RH, Schnitzer TJ, Berenbaum F, Bushmakin AG, Cappelleri JC, Viktrup L, Abraham L  WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee.  J Rheumatol  2022 Jun;49(6):615-621. doi:10.3899/jrheum.210543
  18. Berenbaum F, Schnitzer TJ, Kivitz AJ, Viktrup L, Hickman A, Pixton G, Brown MT, Davignon I, West CR  General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials.  Arthritis Care Res (Hoboken)  2022 Jun;74(6):918-928. doi:10.1002/acr.24637
  19. Schnitzer TJ, Robinson RL, Tive L, Cappelleri JC, Bushmakin AG, Jackson J, Berry M, Barlow S, Walker C, Viktrup L  Factors associated with physician-reported treatment status of patients with osteoarthritis pain.  BMC Musculoskelet Disord  2022 May 26;23(1):498. pii:498
  20. Vachon-Presseau E, Abdullah TB, Berger SE, Huang L, Griffith JW, Schnitzer TJ, Apkarian AV  Validating a biosignature-predicting placebo pill response in chronic pain in the settings of a randomized controlled trial.  Pain  2022 May 01;163(5):910-922. doi:10.1097/j.pain.0000000000002450
  21. Robinson RL, Schnitzer TJ, Barlow S, Berry M, Bushmakin AG, Cappelleri JC, Tive L, Jackson J, Jackson J, Viktrup L  Satisfaction with Medications Prescribed for Osteoarthritis: A Cross-Sectional Survey of Patients and Their Physicians in the United States.  Pain Ther  2022 Mar;11(1):191-208. doi:10.1007/s40122-021-00350-0
  22. Edwards WB, Haider IT, Simonian N, Barroso J, Schnitzer TJ  Reply to Letter to the Editor Regarding "Durability and Delayed Treatment Effects of Zoledronic Acid on Bone Loss After Spinal Cord Injury: A Randomized, Controlled Trial".  J Bone Miner Res  2022 Jan;37(1):169-170. doi:10.1002/jbmr.4456
  23. Schnitzer TJ, Berenbaum F, Conaghan PG, Dworkin RH, Gatti D, Yang R, Viktrup L, Davignon I, West CR, Verburg KM  Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis.  Rheumatol Ther  2021 Dec;8(4):1759-1774. doi:10.1007/s40744-021-00372-2
  24. Reckziegel D, Tétreault P, Ghantous M, Wakaizumi K, Petre B, Huang L, Jabakhanji R, Abdullah T, Vachon-Presseau E, Berger S  et al.  Sex-Specific Pharmacotherapy for Back Pain: A Proof-of-Concept Randomized Trial.  Pain Ther  2021 Dec;10(2):1375-1400. doi:10.1007/s40122-021-00297-2
  25. Edwards WB, Haider IT, Simonian N, Barroso J, Schnitzer TJ  Durability and delayed treatment effects of zoledronic acid on bone loss after spinal cord injury: a randomized, controlled trial.  J Bone Miner Res  2021 Nov;36(11):2127-2138. doi:10.1002/jbmr.4416
  26. Hochberg MC, Carrino JA, Schnitzer TJ, Guermazi A, Walsh DA, White A, Nakajo S, Fountaine RJ, Hickman A, Pixton G  et al.  Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.  Arthritis Rheumatol  2021 Jul;73(7):1167-1177. doi:10.1002/art.41674
  27. Wakaizumi K, Vigotsky AD, Jabakhanji R, Abdallah M, Barroso J, Schnitzer TJ, Apkarian AV, Baliki MN  Psychosocial, Functional, and Emotional Correlates of Long-Term Opioid Use in Patients with Chronic Back Pain: A Cross-Sectional Case-Control Study.  Pain Ther  2021 Jun;10(1):691-709. doi:10.1007/s40122-021-00257-w
  28. Troy KL, Mancuso ME, Johnson JE, Butler TA, Ngo BH, Schnitzer TJ  Dominant and nondominant distal radius microstructure: Predictors of asymmetry and effects of a unilateral mechanical loading intervention.  Bone Rep  2021 Jun;14:101012. pii:101012
  29. Reckziegel D, Abdullah T, Wu B, Wu B, Huang L, Schnitzer TJ, Apkarian AV  Hippocampus shape deformation: a potential diagnostic biomarker for chronic back pain in women.  Pain  2021 May 01;162(5):1457-1467. doi:10.1097/j.pain.0000000000002143
  30. Barroso J, Wakaizumi K, Reis AM, Baliki M, Schnitzer TJ, Galhardo V, Apkarian AV  Reorganization of functional brain network architecture in chronic osteoarthritis pain.  Hum Brain Mapp  2021 Mar;42(4):1206-1222. doi:10.1002/hbm.25287
  31. Haider IT, Simonian N, Schnitzer TJ, Edwards WB  Stiffness and Strength Predictions From Finite Element Models of the Knee are Associated with Lower-Limb Fractures After Spinal Cord Injury.  Ann Biomed Eng  2021 Feb;49(2):769-779. doi:10.1007/s10439-020-02606-w
  32. Barroso J, Vigotsky AD, Branco P, Reis AM, Schnitzer TJ, Galhardo V, Apkarian AV  Brain gray matter abnormalities in osteoarthritis pain: a cross-sectional evaluation.  Pain  2020 Sep 01;161(9):2167-2178. doi:10.1097/j.pain.0000000000001904
  33. Troy KL, Mancuso ME, Johnson JE, Wu Z, Schnitzer TJ, Butler TA  Bone Adaptation in Adult Women Is Related to Loading Dose: A 12-Month Randomized Controlled Trial.  J Bone Miner Res  2020 Jul;35(7):1300-1312. doi:10.1002/jbmr.3999
  34. Schnitzer TJ, Khan A, Bessette L, Davignon I, Brown MT, Pixton G, Prucka WR, Tive L, Viktrup L, West CR  Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study.  Semin Arthritis Rheum  2020 Jun;50(3):387-393. doi:10.1016/j.semarthrit.2020.03.004
  35. Smith BC, Vigotsky AD, Apkarian AV, Schnitzer TJ  Temporal Factors Associated With Opioid Prescriptions for Patients With Pain Conditions in an Urban Emergency Department.  JAMA Netw Open  2020 Mar 02;3(3):e200802. pii:e200802
  36. Dakin P, DiMartino SJ, Gao H, Maloney J, Kivitz AJ, Schnitzer TJ, Stahl N, Yancopoulos GD, Geba GP  The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial.  Arthritis Rheumatol  2019 Nov;71(11):1824-1834. doi:10.1002/art.41012
  37. Haider IT, Simonian N, Saini AS, Leung FM, Edwards WB, Schnitzer TJ  Open-label clinical trial of alendronate after teriparatide therapy in people with spinal cord injury and low bone mineral density.  Spinal Cord  2019 Oct;57(10):832-842. doi:10.1038/s41393-019-0303-3
  38. Vachon-Presseau E, Berger SE, Abdullah TB, Griffith JW, Schnitzer TJ, Apkarian AV  Identification of traits and functional connectivity-based neurotraits of chronic pain.  PLoS Biol  2019 Aug;17(8):e3000349. pii:e3000349
  39. Smith TO, Mansfield M, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, Christensen R, Guillemin F, Terwee CB  et al.  Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017.  J Rheumatol  2019 Aug;46(8):976-980. doi:10.3899/jrheum.181066
  40. Smith TO, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, Christensen R, Guillemin F, Terwee CB, Williamson PR  et al.  The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis.  J Rheumatol  2019 Aug;46(8):981-989. doi:10.3899/jrheum.181194
  41. Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, Davignon I, Brown MT, West CR, Verburg KM  Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.  JAMA  2019 Jul 02;322(1):37-48. doi:10.1001/jama.2019.8044
  42. Fleischmann RM, Bliddal H, Blanco FJ, Schnitzer TJ, Peterfy C, Chen S, Wang L, Feng S, Conaghan PG, Berenbaum F  et al.  A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis.  Arthritis Rheumatol  2019 Jul;71(7):1056-1069. doi:10.1002/art.40840
  43. Reckziegel D, Vachon-Presseau E, Petre B, Schnitzer TJ, Baliki MN, Apkarian AV  Deconstructing biomarkers for chronic pain: context- and hypothesis-dependent biomarker types in relation to chronic pain.  Pain  2019 May;160 Suppl 1(Suppl 1):S37-S48. doi:10.1097/j.pain.0000000000001529
  44. Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, West CR  Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip.  J Pain Res  2019;12:975-995. doi:10.2147/JPR.S191297